Search Results

American Regent announces the launch of sulfite-free Epinephrine Injection, USP.

American Regent announces the launch and availability of Potassium Phosphates Injection, USP, which is FDA-approved and therapeutically equivalent to Potassium Phosphates.1 Potassium Phosphates Injection, USP is indicated as a source of phosphorus:

American Regent announces the release and availability of Levocarnitine Injection, USP, FDA-approved, “AP” rated, and therapeutically equivalent to Carnitor®.

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets. • The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™. • TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026. • Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity. • Once required registrations are completed, TempraMed products are expected to be available through distribution relationships covering seven Latin American countries representing a substantial majority of the region’s population. • TempraMed expects to raise up toC$1,000,000 through non-brokered private placement of Units

American Regent, Inc., a Daiichi Sankyo Group company, announced results from the phase 3 HEART-FID trial of INJECTAFER® for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction.

Members of the American Biotech Innovation Alliance (ABIA) want to build a national biotech strategy—just like China did years ago.